

Accepted Manuscript

Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA

Cyril Borie, Shovan Mondal, Tanzeel Arif, Manon Briand, Hugo Lingua, Frédéric Dumur, Didier Gimes, Pierre Stocker, Bernadette Barbarat, Viviane Robert, Cendrine Nicoletti, Daniel Olive, Marc Maresca, Malek Nechab

PII: S0223-5234(18)30160-0

DOI: [10.1016/j.ejmech.2018.02.030](https://doi.org/10.1016/j.ejmech.2018.02.030)

Reference: EJMECH 10207

To appear in: *European Journal of Medicinal Chemistry*


Received Date: 12 December 2017




Revised Date: 9 February 2018

Accepted Date: 10 February 2018

Please cite this article as: C. Borie, S. Mondal, T. Arif, M. Briand, H. Lingua, Frée. Dumur, D. Gimes, P. Stocker, B. Barbarat, V. Robert, C. Nicoletti, D. Olive, M. Maresca, M. Nechab, Enediynes bearing polyfluoroaryl sulfoxide as new antiproliferative agents with dual targeting of microtubules and DNA, *European Journal of Medicinal Chemistry* (2018), doi: 10.1016/j.ejmech.2018.02.030.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Dual activation against pancreatic cancer cells

Enediynes Bearing Polyfluoroaryl Sulfoxide as New Antiproliferative Agents with Dual Targeting of Microtubules and DNA.

Cyril Borie,^a Shovan Mondal,^{a,b} Tanzeel Arif,^a Manon Briand,^a Hugo Lingua,^a Frédéric Dumur,^a Didier Gimes,^a Pierre Stocker,^a Bernadette Barbarat,^{c,d} Viviane Robert,^e Cendrine Nicoletti,^e Daniel Olive,^{c,d} Marc Maresca,^{e*} Malek Nechab^{a*}

^a Aix Marseille Univ, CNRS, Institut de Chimie Radicalaire UMR 7273, F-13390 Marseille, France

^b Department of Chemistry, Syamsundar College, Shyamsundar 713424, West Bengal, India

^c Centre de Recherche en Cancérologie de Marseille (CRCM) UMR-INSERM1068-IBiSA Cancer Immunomonitoring Platform, Inserm, U1068, France

^d Institut Paoli Calmettes, 27, boulevard Lei Roure, BP30059, 13273, Marseille Cedex 09, France

^e Aix Marseille Univ, CNRS, Centrale Marseille, iSm2 UMR 7313, F-13397, Marseille, France

corresponding authors: m.maresca@univ-amu.fr; malek.nechab@univ-amu.fr

Abstract: A novel series of enediynes possessing pentafluorophenylsulfoxide have been developed. The innovative compounds possess antiproliferative activity against a broad panel of human cancer cells originating from breast, blood, lung, kidney, colon, prostate, pancreas or skin with IC₅₀ ranging from 0.6 to 3.4 μ M. The antiproliferative activity of enediynes in darkness is associated to their ability to compromise microtubule network. In addition, exposure to UV leads to double-stranded DNA cleavage caused by the newly synthesized molecules reducing further their IC₅₀ in nanomolar range against human tumor cells, including chemo-resistant pancreatic cancer cells. Taken together, the examined data demonstrate that enediynes possessing pentafluorosulfoxide are promising molecules in the cancer therapy.

Keywords: Enediynes, Anticancer, Microtubules, DNA cleavage, light activation.

1- Introduction

In the last decades, the enediynes derived from natural products, such as calicheamicins, and their synthetic analogues have been used in DNA cleavage studies [1]. These molecules were found as promising therapeutic agents against many types of cancers [2]. Their biological activity stems from cyclization of the enediyne moiety to a highly reactive 1,4-benzenoid diradical [1,3]. The latter is able to abstract hydrogen atoms from the sugar phosphate backbone of adjacent strands of DNA causing scission of the DNA double helix. Despite the great number of enediynes reported to display anti-tumor activities, there is a need of


development of new compounds as potential drugs against chemoresistant cancers like pancreatic tumors. To address this issue, design of novel molecules presenting a dual activity is a challenging task [4].

During our recent interest in cascade reactions involving enediynes [5], we observed a high reactivity of pentafluorophenylsulfone when compared to their non-fluorinated analogues. Non-fluorinated compound **5** (Figure 1) has been reported to exhibit a moderate activity ($IC_{50} \sim 20 \mu M$) against various tumor cells [6]. Because, organic molecules containing fluorine atoms are recognized to provide a high impact in medicinal chemistry [7], we report herein the synthesis of a novel series of enediynes containing polyfluorinatedsulfoxides and their actions against tumor cells related to their dual activity targeting microtubules and DNA photocleavage.

2. Results and discussion

Synthesis

Inspired by a previously designed strategy [6,8], the syntheses of compounds have been realized in 5 steps (Scheme 1). The first step consists of a Sonogashira coupling of protected propargyl alcohol and 1,2-diiodobenzene derivatives using $Pd(PPh_3)_4$ [9]. A second Sonogashira cross coupling afforded the enediynes moiety **2**. The free alcohol was then mesylated and immediately displaced, without any purification, by pentafluorothiophenol to afford the corresponding thioether **3**. The *m*-CPBA oxidation followed by a deprotection with pyridinium *p*-toluenesulfonate (PPTS) afforded the desired products **4a-4k** with satisfactory overall yields (Figure 1).



Scheme 1 Synthetic route for enediynes **4**

In-vitro antiproliferative activities

Propargyl sulfones constitute a class of bioactive compounds acting on DNA and cell division [10]. To this end, we evaluated the capacity of compounds **4-7** to inhibit the proliferation of cancer cells measured by the Alamar Blue assays. The in-vitro antiproliferative effect, expressed as IC_{50} (50% inhibition of the cell proliferation), was first investigated using the human pancreatic tumor cells MIAPaCa-2. These cells were chosen since pancreatic cancer is

a highly aggressive malignant disease with high chemoresistance and thus considerable efforts have to be furnished to solve this problem [11].

We have shown that the structural modification of the enediyne compounds has an influence on the activity against tumor cells. We first demonstrated that the presence of fluorine atoms (**4a**) has a crucial importance as it affords higher efficacy (IC_{50} of 2.6 μM , corresponding to a 6-fold increase compared to **5**). The oxidation state of sulfur has also shown its importance, the sulfoxide **4a** provided a better IC_{50} when it is compared to the sulfone analogue **4b** (IC_{50} of 3.9 μM). The elongation of side chain in **4c** has however exhibited a detrimental effect (IC_{50} of >10 μM). The same observation has been made with naphthyl analogue **4d** (IC_{50} of 4.7 μM). The presence of free alcohol seems to be not imperative for the activity, the azide **4g** revealed the same IC_{50} as **4a** (IC_{50} of 2.4 and 2.5 μM , respectively). However, the presence of the two alkynes has been demonstrated to be important for the activity (IC_{50} of 7.8 μM for compound **4e**). On the other hand, the presence of ethyl ester group on the aromatic ring (**4f**) allows a similar increase in the activity (IC_{50} of 1.6 μM). The thiophene derivative **6** afforded an IC_{50} of 2.2 μM . Finally, the passage to pyridinyl compound **4i** affords the best value of IC_{50} (0.8 μM). Again, the synthesis intermediates **4h** and **4j** confirmed that the presence of hydroxyl group is not essential. Based on these results, we then selected the heterocyclic enediyne **4i** to continue our studies. It is interesting to recall that clinically used antitumor drug 5-fluoracil presents an IC_{50} 6-fold higher than **4i** [10b,12]. Gemcitabine, a widely used difluoro-drug in the treatment of pancreatic cancers [13,14], was then evaluated as a positive control in three independent experiments and showed an IC_{50} in the range 0.12 μM .




Figure 1 Enediynes Structure and their IC_{50} in μM (in brackets) on the proliferation of human pancreatic tumor cells MIAPaCa-2.

Encouraged by these results obtained with pancreatic cancer cells, we screened a broad panel of human cancer cells originating from breast, blood, lung, kidney, colon, prostate or skin (Table 1). Results showed that compound **4i** is active against all cancer cell types tested, exhibiting promising IC_{50} ranging from 0.6 to 3.4 μM , with K562 and MOLT-4 cells (blood cancer) showing the highest efficacy whereas the renal cell line A498 revealed the lowest sensitivity. This result suggests that this class of compounds can be used potentially to treat various forms and types of cancers [15].

Table 1: IC_{50} values of **4i** in different cells

Cell lines	IC_{50} (μM)
MIAPaCa-2 (pancreas)	0.8 ± 0.1
MDA-MB 231 (breast)	1.2 ± 0.1
K562 (blood)	0.7 ± 0.08
MOLT-4 (blood)	0.6 ± 0.06
A549 (lung)	1.6 ± 0.18
A498 (kidney)	3.4 ± 0.2
CaCo-2 (colon)	1.0 ± 0.12
PC-3 (prostate)	1.4 ± 0.1
A431 (melanoma)	1.5 ± 0.1

GERL 3.0 (melanoma)

 0.9 ± 0.1

We have then investigated the antiproliferative and cytotoxic action of enediyne **4i** regarding normal / primary human cells and compared them to results obtained with MIA PaCa-2 (Table 2). The IC_{50} of enediyne **4i** on cell proliferation on normal human cells ranged from 0.6 to 1.40 μ M, demonstrating that the antiproliferative effect of enediyne **4i** was not selective of cancer cells. Similar results were found with enediyne **5** (Table 2). This absence of selectivity of enediynes is not surprising as it was also observed with other antiproliferative drugs such as doxorubicin and T138067 (Table 2). Importantly, when we measured the impact of enediyne **4i** on cell viability with confluent cells, we found that it caused cytotoxicity at much higher doses in all cell tested (Table 2) with IC_{50} on cell viability ranging from 8.8 to 27.1 μ M, corresponding to a 14 to 25-fold difference between the IC_{50} values on proliferation versus on cell viability. T138067 and doxorubicin showed lower fold differences between their antiproliferative and cytotoxic effects, except for the normal breast cells HBL-100 for which the fold difference was >190 and 106-fold difference for T138067 and doxorubicin, respectively, suggesting major difference in their toxic effect depending of cell types. Finally, enediyne **5** caused also cell toxicity at doses much closer from the ones inhibiting cell proliferation (0.8 to 7.8-fold difference). All together these results underlie the antiproliferative nature of enediyne **4i** and its relative safety in term of cell toxicity compared to other antiproliferative drugs tested.

Table 2: Comparative effect of different drugs on proliferative and confluent human cells (IC_{50} are expressed in μ M).

Cell name	Cell type	Drug	IC_{50} on cell proliferation	IC_{50} on cell viability	Fold variation
BEAS	Normal (Airway)	4i	1.0 ± 0.02	19.6 ± 0.8	18.6
		5	29.5 ± 0.7	81.9 ± 3.4	2.8
		T138067	12.2 ± 0.4	> 40	> 3.2
		Doxorubicin	2.4 ± 0.08	18.6 ± 0.9	7.8
HBL-100	Normal (Breast)	4i	1.4 ± 0.01	27.1 ± 0.8	19.3
		5	19.0 ± 0.4	35.4 ± 3.2	1.8
		T138067	0.2 ± 0.01	> 40	> 190
		Doxorubicin	0.08 ± 0.01	8.5 ± 2.1	106
HUVEC	Normal (Endothelium)	4i	0.6 ± 0.02	8.8 ± 0.2	14
		5	79.8 ± 3.2	66.2 ± 1.6	0.8
		T138067	6.3 ± 0.36	16.4 ± 0.70	2.6
		Doxorubicin	0.15 ± 0.03	0.48 ± 0.06	3.2
MIA PaCa-2	Cancer (Pancreas)	4i	0.8 ± 0.03	20.5 ± 2.2	25.3
		5	15.9 ± 0.7	124 ± 9	7.8
		T138067	1.3 ± 0.06	47.3 ± 4.5	35.8
		Doxorubicin	0.4 ± 0.02	3.1 ± 0.4	6.8

Mechanism of action.

Based on their chemical structure, the mechanism by which compound **4** is giving biological activity was first hypothesized to be related to DNA break. As already mentioned in the introduction, biradicals issued from Bergman cyloaromatization (or Saito Myers cyclization) are able to abstract hydrogen atom from DNA backbone [1b]. Moreover, propargyl sulfones (or their allenic analogs) were already reported to act as alkylating agent [10b,16]. In order to confirm such activity, we investigated the ability of Eneidyne **4a** and **4i** to cleave DNA using supercoiled plasmid pCDNA3 at 100 μ M concentration of the compounds. Surprisingly, intact DNA was recovered demonstrating that no cleavage is caused by these compounds.

Since DNA break was not involved in the anti-proliferative action of our compounds and questioned by the result seen with compound devoid of enediyne moiety **4e** (Figure 1), we therefore turned our reflection to an alternative hypothesis. Indeed, a known anti-proliferative compound called T138067 sharing with our compounds the perfluorinated moiety (Figure 2) [17,18]. T138067 has been shown to act via a nucleophilic substitution in para position of its perfluorinated moiety allowing the binding of the molecule to a cysteine residue (Cys239) of tubulin resulting in microtubules depolymerisation and inhibition of the cell proliferation [17c]. We thus investigated if compounds **4** containing also the perfluorinated moiety possess anti-microtubules activity.

Indeed, pyridinyl compound **4i** bears a parafluorobenzene sulfoxide, a molecular function that could act as a binding site through the nucleophilic attack of a thiol. Action against microtubules was thus investigated. A498 cells were treated with **4i**, T138067 or with colchicine (two molecules known to affect microtubules network) for 1, 3, 6 and 12h before labelling of microtubules with antibodies directed against β -tubulin (Figure 2). Results showed that although the action of compound **4i** is slower than T138067 or colchicine, it results in a clear impact on microtubules integrity.




Figure 2: Time-dependent effect of compound **4i on microtubule network in A498 cells.** A498 cells were exposed for 1, 3, 6 or 12 h to compound **4i** at 5 times its IC_{50} value determined in proliferation assay. Cells were fixed and microtubule network (in green) was immunolabelled with antibody directed against beta tubulin.

Similarly, **4i** treatment leads to alteration of the microtubules network in A549 and MIAPaCa-2 cells (Figure 3). The same result was obtained with other compounds of this family, with the exception of the non perfluorinated compound **5** (Figure 4). This compound bore a fully hydrogenated moiety and consequently showed no action on microtubules integrity. This result supports the hypothesis of the involvement of the fluorinated part of this family in an antimicrotubule activity, probably at the origin of their antiproliferative action on cancer cells.




Figure 3: Effect of compound 4i on microtubule network of different cancer cells. A498, A549 and MIAPaCa-2 cells were exposed for 12 h to compound 4i at 5 time its IC_{50} value on each cell type determined in proliferation assay. After 12 h, cells were fixed and microtubule network (in green) was immunolabelled with antibody directed against beta tubulin.




Figure 4: Effect of compounds 4d, 4a and 5 on microtubule network of different cancer cells. A498, A549 and MIAPaCa-2 cells were exposed for 12 h to compounds Colchicine, T138067 4d, 4a and 5, respectively at 5 time their IC_{50} value determined in proliferation assay. After 12 h, cells were fixed and microtubule network (in green) was immunolabelled with antibody directed against beta tubulin.

Photocleavage:

Since drug resistance is the major cause of failure of chemotherapeutics for further development, we thought that a drug possessing a dual activity will be more promising. Settling of the sulfoxide moiety was judiciously planned to this issue. Indeed, sulfoxide is known to be photochemically sensible [19] and more interestingly, it has been demonstrated that this entity is able to trigger DNA photocleavage [20]. The above enediynes were naturally investigated regarding their ability for DNA cleavage, upon excitation by light, using a plasmid relaxation assays [21]. So, although our compounds do not cause DNA break in the dark (Figure 6), we investigated if excitation by light leads to DNA cleavage [22]. The control experiments in the dark confirm the results of Figure 5 that the compounds are not able to cleave DNA. On another hand, when the compounds were irradiated, a full DNA cleavages were observed and more importantly, a double-stranded cleavage (form III) was detected on gel. This break is known to be more difficult to repair by enzymes and thus provides a better chance to initiate a cell death [23].




Figure 5. Photochemical cleavage ($\lambda = 365$ nm during 1h) of pCDNA3 supercoiled DNA (20 μ M/bp) by **4i** (100 μ M) in TE buffer.

Table 3: Antiproliferative activity, expressed as IC_{50} (in μ M), of Enediyne **4i** in the absence or presence of light (10 minutes at 365 nm)

Cell-line	IC_{50} (in μ M) in dark	IC_{50} (in μ M) with light	Selectivity factor
MIAPaCa-2	0.8 ± 0.1	0.2 ± 0.05	3.7
MDA-MB 231	1.2 ± 0.1	0.5 ± 0.1	2.2
MOLT-4	0.6 ± 0.06	0.4 ± 0.05	1.6
A549	1.6 ± 0.18	0.8 ± 0.1	2
A498	3.4 ± 0.2	3.2 ± 0.3	1.1
CaCo-2	1.0 ± 0.12	0.5 ± 0.17	2
PC-3	1.4 ± 0.1	0.5 ± 0.14	2.5
A431	1.5 ± 0.1	1.1 ± 0.07	1.3
GERL 3.0	0.9 ± 0.1	0.6 ± 0.07	1.4

We then investigated if photo-activation of compound **4i** increases its anti-proliferative effect on cancer cells. The Alamar Blue assay was used in the same conditions as above to

determine the relative viability upon irradiation at 365 nm during 10 minutes with low energy of 0.6 J/cm^2 . The results are summarized in Table 3. By comparing the dark and light-exposed conditions, we calculated an enhancement factor as the selectivity ratio of activity of compound **4i** in the presence and absence of light. Results showed an increased efficiency in the presence of light in all of cell lines tested, particularly in the case of MIAPaCa-2, with a factor of 3.7 being reached with an anti-proliferative activity of $0.23 \text{ }\mu\text{M}$ after light exposure. We then screened the pyridinyl derivatives **4h**, **4j** and **4k** regarding their ability to phototrigger cytotoxicity against MIAPaCa-2. Interestingly, the ester **4k** has shown the best selectivity of factor 6 (IC_{50} of $3 \text{ }\mu\text{M}$ in the dark and $0.5 \text{ }\mu\text{M}$ in the presence of light).

Conclusion

In this study, we have synthesized a dozen of enediynes that have been evaluated against pancreatic tumor cells (MIAPaCa-2). The pyridinyl enediyne **4i** revealed the highest antiproliferative activity (IC_{50} of $0.8 \text{ }\mu\text{M}$). This compound was also active against the proliferation of a broad panel of human cancer cells like breast, blood, lung, kidney, colon, prostate and skin. Mechanistic study showed that **4i** affects microtubules network which was unprecedented for such family of compound. Additionally, thanks to the presence of the sulfoxide moiety, we have succeeded in a photoactivation process which increases the antiproliferative activity up to 3.71 times (IC_{50} reduced from 0.861 to $0.232 \text{ }\mu\text{M}$). DNA plasmid assays, confirmed the ability of this enediyne to trigger a double-strand cleavage. Importantly, although the antiproliferative effect of enediyne **4i** is poorly selective, affecting the division of both normal and cancer cells, its limited cell toxicity (14 to 25-fold difference between the IC_{50} values on proliferation and cell viability) make it a potential new drug to fight cancer.

3. Experimental Section

Chemical synthesis of enediynes

All reactions were carried out in dry glassware using magnetic stirring and a positive pressure of argon. Solvents are commercially available, most of them were used as purchased (analytical grade), without further purification. DCM was collected from a solvent purification system. THF

and Et_2O were distilled over sodium benzophenone ketyl prior to use. Dry state adsorption conditions and purification were performed on silica gel $60 \text{ }\text{\AA}$ (70-230 mesh). Analytical thin layer chromatography was performed on pre-coated silica gel plates. Visualization was accomplished by UV (254 nm) and with phosphomolybdic acid in ethanol. ^1H NMR spectra were recorded on 400 MHz and ^{13}C spectra were recorded at 100 MHz or 75 MHz. Chemical shifts (δ) are reported in ppm. Signals due to residual protonated solvent (^1H NMR) or to the solvent (^{13}C NMR) served as the internal standard: CDCl_3 (7.26 ppm and 77.16 ppm). Multiplicity is indicated by one or more of the following: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad). The lists of coupling constants (J) correspond to the order of multiplicity assignment and are reported in Hertz (Hz). Whenever necessary, APT, HMQC and HMBC sequences (when necessary) were used for ^{13}C spectra assignment. All melting

points were uncorrected and were recorded in open capillary tubes using a Buchi melting point apparatus. High resolution mass spectra were obtained on QStar Elite (Applied Biosystems SCIEX).

The enediyne **4a** (250 mg) was prepared by using the procedure detailed in supporting information. white solid. m.p.=100 °C. **¹H NMR (400 MHz, CDCl₃) δ:** 7.41 (1H, dd, *J*=6.5 and 1.5 Hz, CH_{ar}), 7.32-7.24 (3H, m, CH_{ar}), 4.52 (1H, d, A part of AB system, *J*=15.8 Hz, CH₂), 4.49 (2H, s, superimposed CH₂), 4.36 (1H, d, B part of AB system, *J*=15.7 Hz, CH₂), 2.75 (1H, bs, OH). **¹³C NMR (100 MHz, CDCl₃) δ:** 132.0 (CH_{ar}), 131.9 (CH_{ar}), 129.1 (CH_{ar}), 128.3 (CH_{ar}), 126.1 (C_{ar}), 124.0 (C_{ar}), 92.6 (C_{C≡C}), 87.9 (C_{C≡C}), 83.5 (C_{C≡C}), 80.6 (C_{C≡C}), 51.6 (CH₂), 46.3 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃) δ:** -137.9 (2F), -145.2 (1F), -158.2 (2F). **HRMS (ESI):** *m/z*: calcd for [M+Na]⁺ C₁₈H₉O₂SF₅Na: 407.0135, found: 407.0136.

The enediyne **4b** (130 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ:** 7.42 (1H, d, *J*=7.4 Hz, CH_{ar}), 7.36-7.24 (3H, m, CH_{ar}), 4.51 (4H, s, 2xCH₂), 2.23 (1H, ls, OH). **¹³C NMR (100 MHz, CDCl₃) δ:** 132.1 (CH_{ar}), 132.0 (CH_{ar}), 129.4 (CH_{ar}), 128.2 (CH_{ar}), 126.3 (C_{ar}), 123.5 (C_{ar}), 92.7 (C_{C≡C}), 88.3 (C_{C≡C}), 83.2 (C_{C≡C}), 77.8 (C_{C≡C}), 51.6 (CH₂), 51.2 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃) δ:** -134.5 (2F), -141.4 (1F), -157.4 (2F). **HRMS (ESI):** *m/z*: calcd for [M+NH₄]⁺ C₁₈H₁₃NF₅O₃S : 418.0531, found: 418.0526.

The enediyne **4c** (350 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ:** 7.36 (1H, d, *J*=7.8 Hz), 7.27-7.16 (3H, m), 4.56 (1H, d, A part of AB, *J*=15.6 Hz), 4.50 (1H, d, B part of AB, *J*=15.6 Hz), 3.71 (2H, t, *J*=6.3 Hz), 2.48 (2H, t, *J*=6.8 Hz), 1.82-1.65 (5H, m). **¹³C NMR (100 MHz, CDCl₃) δ:** 132.2 (CH_{ar}), 132.1 (CH_{ar}), 129.0 (CH_{ar}), 127.5 (CH_{ar}), 126.9 (C_{ar}), 123.5 (C_{ar}), 94.9 (C_{C≡C}), 88.2 (C_{C≡C}), 79.5 (C_{C≡C}), 79.2 (C_{C≡C}), 62.5 (CH₂), 45.8 (CH₂), 31.9 (CH₂), 25.0 (CH₂), 19.4 (CH₂). **¹⁹F NMR (400 MHz, CDCl₃) δ:** -137.6 (2F), -145.5 (1F), -158.5 (2F). **HRMS (ESI):** *m/z*: calcd for [M+Na]⁺ C₂₁H₁₅O₂SF₅Na: 449.0605, found: 449.0605.

The enediyne **4d** (57 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ:** 7.94 (1H, s, CH_{ar}), 7.86 (1H, s, CH_{ar}), 7.75 (2H, m, CH_{ar}), 7.51 (2H, m, CH_{ar}), 4.57 (1H, A part of an AB system, d, *J*=15.8 Hz, CH₂), 4.54 (2H, s, CH₂), 4.39 (1H, B part of an AB system, d, *J*=15.6 Hz, CH₂), 2.81 (1H, ls, OH). **¹³C NMR (100 MHz, CDCl₃) δ:** 132.8 (C_{ar}), 132.5 (CH_{ar}), 132.2 (C_{ar}), 132.1 (CH_{ar}), 128.0 (CH_{ar}), 127.8 (2xCH_{ar}), 127.7 (CH_{ar}), 121.9 (C_{ar}), 120.5 (C_{ar}), 91.9 (C_{C≡C}), 88.1 (C_{C≡C}), 83.6 (C_{C≡C}), 80.2 (C_{C≡C}), 51.6 (CH₂), 46.4 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃) δ:** -137.9 (2F), -145.1 (1F), -158.1 (2F). **HRMS (ESI):** *m/z*: calcd for [M+H]⁺ C₂₂H₁₂F₅O₂S : 435.0473, found: 435.0468.

The compound **4e** (288 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ:** 7.38-7.25 (5H, m, CH_{arom}), 4.51 (1H, d, A part of AB pattern, *J*=15.6 Hz, CH₂), 4.36 (1H, d, B part of AB pattern, *J*=15.6 Hz, CH₂). **¹³C NMR (100 MHz, CDCl₃) δ:** 133.3 (CF_{ar}), 131.8 (CH_{ar}), 129.7 (CF_{ar}), 129.4 (CH_{ar}), 128.7 (CF_{ar}), 128.65 (CH_{ar}), 125.2 (C-C_{ar}), 121.3 (C-S(O)), 86.4 (C_{C≡C}), 76.0 (C_{C≡C}), 45.5 (CH₂). **¹⁹F**

NMR (400 MHz, CDCl₃) δ : -138.8 (2F), -146.8 (1F) -159.8 (2F). **HRMS (ESI): m/z :** calcd for [M+H]⁺ C₁₅H₇F₅SO : 331.0211, found: 331.0209.

The enediyne **4f** (83 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ :** 7.99 (1H, s, CH_{ar}), 7.96 (1H, d, J =8.1 Hz, CH_{ar}), 7.48 (1H, d, J =8.1 Hz, CH_{ar}), 4.56-4.52 (1H, d, A part of AB system, J =16.0 Hz, CH₂), 4.52 (2H, s, superimposed CH₂), 4.40-4.35 (2H, q, J =7.1 Hz, CH₂), 4.35-4.32 (1H, d, B part of AB system, J =15.8 Hz, CH₂), 2.91 (1H, lt, J =6.1 Hz, OH), 1.39 (3H, t, J =7.1 Hz, CH₃). **¹³C NMR (100 MHz, CDCl₃) δ :** 165.2 (C=O), 133.0 (CH_{ar}), 131.9 (CH_{ar}), 130.2 (2xCH_{ar}), 129.9 (CH_{ar}), 124.2 (C_{ar}), 95.7 (C_{C≡C}), 87.0 (C_{C≡C}), 83.0 (C_{C≡C}), 81.5 (C_{C≡C}), 61.6 (CH₂), 51.6 (CH₂), 46.3 (CH₂), 14.4 (CH₃). **¹⁹F NMR (376 MHz, CDCl₃) δ :** -137.9 (2F), -144.8 (1F), -157.8 (2F). **HRMS (ESI): m/z :** calcd for [M+Na]⁺ C₂₁H₁₃O₄SF₅Na : 479.0347, found: 479.0345.

The enediyne **4g** (278 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ :** 7.45-7.44 (1H, m, CH_{ar}), 7.33-7.26 (3H, m, CH_{ar}), 4.55 (1H, A part of an AB system, d, J =15.6 Hz, CH₂), 4.44 (1H, B part of an AB system, d, J =15.6 Hz, CH₂). **¹³C NMR (100 MHz, CDCl₃) δ :** 132.6 (CH_{ar}), 132.4 (CH_{ar}), 129.2 (CH_{ar}), 128.8 (CH_{ar}), 124.9 (C_{ar}), 124.0 (C_{ar}), 87.5 (C_{C≡C}), 85.44 (C_{C≡C}), 85.41 (C_{C≡C}), 80.5 (C_{C≡C}), 45.8 (CH₂), 40.7 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃) δ :** -137.7 (2F), -145.4 (1F), -158.4 (2F). **HRMS (ESI): m/z :** calcd for [M+H]⁺ C₁₈H₉N₃OSF₅ : 410.0381, found: 410.0383.

The enediyne **5** (115 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ :** 7.77-7.74 (2H, m, CH_{ar}), 7.54-7.52 (3H, m, CH_{ar}), 7.43 (1H, d, J =7.5 Hz, CH_{ar}), 7.34-7.21 (3H, m, CH_{ar}), 4.53 (2H, s, CH₂), 4.21 (1H, ls, OH), 3.97 (1H, d, A part of AB system, J =16.1 Hz, CH₂), 3.80 (1H, d, B part of AB system, J =16.1 Hz, CH₂). **¹³C NMR (100 MHz, CDCl₃) δ :** 142.5 (C_{ar}), 131.9 (CH_{ar}), 131.6 (CH_{ar}), 131.4 (CH_{ar}), 129.4 (2xCH_{ar}), 128.6 (CH_{ar}), 127.9 (CH_{ar}), 126.5 (C_{ar}), 125.0 (C_{ar}), 124.5 (2xCH_{ar}), 93.3 (C_{C≡C}), 87.0 (C_{C≡C}), 83.6 (C_{C≡C}), 82.2 (C_{C≡C}), 51.5 (CH₂), 49.4 (CH₂). **HRMS (ESI): m/z :** calcd for [M+Na]⁺ C₁₈H₁₄O₂SNa : 317.0607, found: 317.0608.

The enediyne **4h** (285 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ :** 8.46 (1H, dd, J =4.8 and 1.5 Hz, CH_{ar}), 7.52 (1H, dd, J =7.9 and 1.6 Hz, CH_{ar}), 7.13 (1H, dd, J =7.9 and 4.9 Hz, CH_{ar}), 4.89 (1H, s, CH), 4.52-4.36 (4H, m, CH₂), 3.82-3.76 (1H, m, CH₂), 3.52-3.49 (1H, m, CH₂), 1.79-1.50 (6H, m, CH₂). **¹³C NMR (100 MHz, CDCl₃) δ :** 149.7 (CH_{ar}), 144.9 (C_{ar}), 139.3 (CH_{ar}), 122.4 (CH_{ar}), 121.1 (C_{ar}), 96.6 (CH), 90.1 (C_{C≡C}), 85.4 (C_{C≡C}), 83.6 (C_{C≡C}), 82.9 (C_{C≡C}), 61.9 (CH₂), 54.3 (CH₂), 45.7 (CH₂), 30.3 (CH₂), 25.5 (CH₂), 18.9 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃) δ :** -137.7 (2F), -145.0 (1F), -158.2 (2F). **HRMS (ESI): m/z :** calcd for [M+H]⁺ C₂₂H₁₇F₅NO₃S : 470.0844, found: 470.0845.

The enediyne **4i** (74 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃) δ :** 8.53 (1H, dd, J =5.0 and 1.5 Hz, CH_{ar}), 7.65 (1H, dd, J =7.9 and 1.5 Hz, CH_{ar}), 7.21 (1H, dd, J =7.9 and 5 Hz, CH_{ar}), 4.54 (1H, A part of an AB system, d, J =16.1 Hz, CH₂), 4.52 (2H, s, superimposed CH₂), 4.34 (1H, B part of an AB

system, d, $J=16.1$ Hz, CH₂), 3.03 (1H, s, OH). **¹³C NMR (100 MHz, CDCl₃)** δ : 149.7 (CH_{ar}), 145.3 (C_{ar}), 139.1 (CH_{ar}), 122.3 (CH_{ar}), 121.1 (C_{ar}), 92.9 (C_{C=C}), 85.5 (C_{C=C}), 83.6 (C_{C=C}), 83.2 (C_{C=C}), 51.4 (CH₂), 46.3 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃)** δ : -138.0 (2F), -144.7 (1F), -157.8 (2F). **HRMS (ESI):** m/z : calcd for [M+H]⁺ C₁₇H₉F₅NO₂S : 386.0269, found: 386.0265.

The enediyne **4j** (97 mg) was prepared by using the procedure detailed in supporting information. **¹H NMR (400 MHz, CDCl₃)** δ : 8.52 (1H, dd, $J=4.9$ and 1.6 Hz, CH_{ar}), 7.59 (1H, dd, $J=7.9$ and 1.6 Hz, CH_{ar}), 7.20 (1H, dd, $J=7.9$ and 4.9 Hz, CH_{ar}), 4.88 (2H, d, $J=1.5$ Hz, CH), 4.56 (1H, A part of AB pattern, d, $J=15.8$ Hz, CH₂), 4.50 (2H, s, CH₂), 4.47 (1H, B part of AB pattern, d, $J=15.8$ Hz, CH₂), 3.75 (2H, m, CH₂), 3.58 (2H, m, CH₂), 3.39 (3H, s, CH₃). **¹³C NMR (100 MHz, CDCl₃)** δ : 149.8 (CH_{ar}), 144.8 (C_{ar}), 139.4 (CH_{ar}), 122.5 (C_{ar}), 121.1 (CH_{ar}), 93.8 (CH₂), 89.5 (C_{C=C}), 85.3 (C_{C=C}), 83.9 (C_{C=C}), 83.1 (C_{C=C}), 71.8 (CH₂), 67.4 (CH₂), 59.1 (CH₃), 54.6 (CH₂), 45.7 (CH₂). **¹⁹F NMR (376 MHz, CDCl₃)** δ : -137.8 (2F), -145.0 (1F), -158.2 (2F). **HRMS (ESI):** m/z : calcd for [M+H]⁺ C₂₁H₁₇NO₄SF₅ : 474.0793, found: 474.0792.

4. Material and Methods

Cell culture

Human cancer cell lines and normal cells were obtained from American Type Culture Collection (ATCC). HUVEC cells were grown in defined all-in-one ready to use endothelial cell growth medium (Sigma Aldrich). Other cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (FCS, Lonza) at 37 °C in a 100% humidified atmosphere containing 5% CO₂. Cells were sub-cultured in new media every 3-4 days and were regularly checked for mycoplasma contamination and remained negative throughout the experiments.

Cell proliferation and cell viability assay

Antiproliferative and cytotoxic effect were measured using alamar blue. Briefly, for the antiproliferative assay, cells were detached from growing flask using trypsin, cells were counted using the Cellometer Auto T4 apparatus (Nexcelom Bioscience LLC) automated cell counting technique and 0.2% trypan blue reagent (Aldrich) and were seeded in 96 well-plates in the growth media overnight at an initial cell density of 2000 cells/well. For the cell viability assay, cells were detached from growing flask using trypsin, counted and seeded in 96 well-plates in the growth media at an initial cell density of 10,000 cells/well. Cells were then left to grown until they reached complete confluence (generally 2-3 days) before exposure to drugs. Stock solutions of molecules were prepared in DMSO. Proliferative and confluent cells were exposed to increasing concentrations of compounds, in all case resulting in the presence of 0.1% (v:v) DMSO, control cells receiving only DMSO. Cells were then incubated for 70 h, and the cell viability was assessed with CellTiter-Blue® Cell Viability Assay (Promega). 20 μ L of resazurin stock solution was added to the treatment media per well. After 8 h incubation, the fluorescence was recorded at an excitation/emission wavelength of 560/590 nm, with a microplate reader (FLUOstar OPTIMA, BMG Labtech). The fluorescence

measurement was normalized using culture medium without cells. Values measured were adjusted to negative control value (exposure to 0.1% DMSO alone). Data are expressed as the means \pm standard deviation (SD) of three independent experiments, each with triplicate measurements. Data were analyzed with Origin 6.0 software. The IC₅₀ values of each compound on cell proliferation and cell viability were obtained from the dose-dependent curve fit.

Cell proliferation assays upon photoactivation

The cells were prepared with the same protocol as in the dark experiments. After 4h incubation with the enediynes, light activation was achieved by irradiating the cells, at room temperature for 10 min using a transilluminator (8W 365 nm tubes, 30% intensity ie $\approx 0,6$ J/cm² energy, Biostep). As a control, the antiproliferative activity of the tested compounds was also assessed without UV light activation, the plate being protected with aluminium foil during UV irradiation. The intensity of UV light irradiation was determined with a UV radiometer (VLX-3W, Vilber Lourmat) with a 365 nm sensor. After irradiation, cells were incubated for 70 h, and the cell viability was assessed with CellTiter-Blue®. Data are expressed as the means \pm standard deviation (SD) of three independent experiments, each with triplicate measurements. Data were analyzed with Origin 6.0 software. The IC₅₀ values of each compound were obtained from the dose-dependent curve fit.

Plasmid DNA Photocleavage cleavage

Compound **4** in DMSO (1 mM) was added to the solution of supercoiled pCDNA3 (5446 pb, 0.5 μ g) in TE buffer (tris-HCl + EDTA, 20 μ L, pH 8) to reach 100 μ M of **4** as a final concentration. Samples were placed at a distance of 20 cm from LED source (Shimadzu LC-L5, 365 nm) and irradiated at 37 °C during 1 hour. Crude mixtures were then subjected to gel electrophoresis (0.8% agarose containing SYBR® Safe DNA gel Stain) in TAE 0.5X for 1 h at 100 V, then pictures were taken thanks to FluorChem-Q apparatus equipped with filter.

Microtubules immunofluorescence

Cells were seeded in 24-well plates at 10.000 cells/cm² on glass coverslips. After 48 h, compounds dissolved in DMSO were added. After pre-defined times, cells were fixed with 0.5 mL 4% PFA for 20 min at room temperature. After three washes with PBS, cells were saturated and permeabilized for 1 h at room temperature using PBS containing BSA at 2% and Triton X100 at 0.1%. Primary antibody directed against beta-tubulin was then added (mouse anti-human beta tubulin, sc-398937 from Santa Cruz, diluted at 1:100 in PBS/BSA 2% accordingly to manufacturer's instructions). After three washes with PBS, cells were treated with secondary antibody directed against mouse IgG (goat anti-mouse IgG, coupled to Alexa488 Green fluorochrome from Invitrogen diluted at 1:200 in PBS/BSA 2%). After 1 h incubation at room temperature, cells were washed three times with PBS and coverslips were mounted with vectashield liquid, sealed with nailpolish and observed by optical epifluorescence microscope (objective 40x, magnification factor x1.6, Leica DMRB, equipped with Leica DFC 450C camera).

Acknowledgement

Financial assistance from ANR JCJC MOCER2, Région PACA, Aix-Marseille University is acknowledged.

-
- [1] For reviews see: (a) K.C. Nicolaou, A.L. Smith, E.W. Yue, Chemistry and biology of natural and designed enediynes, *Proc. Natl. Acad. Sci.* 90 (1993) 5881–5888; (b) M. Kar, A. Basak, *Chem. Rev.* 107 (2007) 2861–2890.
- [2] R.-G. Shao, *Curr. Mol. Pharmacol.* 1 (2008) 50–60.
- [3] (a) J.M.N. San Pedro, T.A. Beerman, M.M. Greenberg, *Bioorg. Med. Chem.* 20 (2012) 4744–4750; (b) R.K. Mohamed, P.W. Peterson, I.V. Alabugin, *Chem. Rev.* 113 (2013) 7089–7129.
- [4] J.-B. Chen, T.-R. Chern, T.-T. Wei, C.-C. Chen, J.-H. Lin, J.-M. Fang, *J. Med. Chem.* 56 (2013) 3645–3655.
- [5] (a) M. Nechab, D. Campolo, J. Maury, P. Perfetti, N. Vanthuyne, D. Siri, M.P. Bertrand, *J. Am. Chem. Soc.* 132 (2010) 14742–14744; (b) M. Nechab, E. Besson, D. Campolo, P. Perfetti, N. Vanthuyne, E. Bloch, R. Denoyel, M.P. Bertrand, *Chem. Commun.* 47 (2011) 5286–5288; (c) D. Campolo, A. Gaudel-Siri, S. Mondal, D. Siri, E. Besson, N. Vanthuyne, M. Nechab, M.P. Bertrand, *J. Org. Chem.* 77 (2012) 2773–2783; (d) A. Gaudel-Siri, D. Campolo, S. Mondal, M. Nechab, D. Siri, M.P. Bertrand, *J. Org. Chem.* 79 (2014) 9086–9093; (e) D. Campolo, T. Arif, C. Borie, D. Mouysset, N. Vanthuyne, J.-V. Naubron, M.P. Bertrand, M. Nechab, *Angew. Chem. Int. Ed.* 53 (2014) 3227–3231.
- [6] (a) M.-J. Wu, C.-F. Lin, J.-S. Wu, H.-T. Chen, *Tetrahedron Lett.* 35 (1994) 1879–1882; (b) M.-J. Wu, C.-F. Lin, C.-W. Ong, *Bioorg. Med. Chem. Lett.* 6 (1996) 675–8.
- [7] (a) J. Wang, M. Sánchez-Roselló, J.L. Aceña, C. del Pozo, A.E. Sorochinsky, S. Fustero, V.A. Soloshonok, H. Liu, *Chem. Rev.* 114 (2014) 2432–2506; (b) J. Wang, M. Sánchez-Roselló, J.L. Aceña, C. del Pozo, A.E. Sorochinsky, S. Fustero, V.A. Soloshonok, H. Liu, *Chem. Rev.* 114 (2014) 2432–2506.
- [8] (a) S. Mondal, A. Basak, S. Jana, A. Anoop, *Tetrahedron.* 68 (2012) 7202–7210; (b) S. Roy, S.S. Bag, A. Basak, *Tetrahedron.* 68 (2012) 8600–8611.
- [9] S. Mondal, F. Dumur, B. Barbarat, O. Grauby, D. Gimes, D. Olive, M.P. Bertrand, M. Nechab, *Colloids Surf. B Biointerfaces.* 112 (2013) 513–520.
- [10] (a) D. Mitra, D.R. Banerjee, A.K. Das, A. Basak, *Bioorg. Med. Chem. Lett.* 20 (2010) 6831–6835; (b) W.-M. Dai, Chun Wo Chow, Ling Zhou, A. Ishii, Chi Wai Lau, Quan Li, W. Hamaguchi, S. Nishimoto, *Bioorg. Med. Chem. Lett.* 9 (1999) 2789–2794; (c) A. Basak, S. Das, D. Mallick, E.D. Jemmis, *J. Am. Chem. Soc.* 131 (2009) 15695–15704.
- [11] Z. Wang, Y. Li, A. Ahmad, S. Banerjee, A.S. Azmi, D. Kong, F.H. Sarkar, *Nat. Rev. Gastroenterol. Hepatol.* 8 (2011) 27–33.
- [12] M. Tsujie, S. Nakamori, S. Nakahira, Y. Takahashi, N. Hayashi, J. Okami, H. Nagano, K. Dono, K. Umeshita, M. Sakon, M. Monden, *Anticancer Res.* 27 (2007) 2241–2249.
- [13] M.J. Rathos, K. Joshi, H. Khanwalkar, S.M. Manohar, K.S. Joshi, *J. Transl. Med.* 10 (2012) 161.
- [14] L.R. Jaidev, U.M. Krishnan, S. Sethuraman, *Mater. Sci. Eng. C.* 47 (2015) 40–47.

- [15] Doxorubicin was used as a positive control in PC-3, MDA-MB 231, K562 and MOLT-4 and showed 10-fold higher activity than **4i**.
- [16] (a) K.C. Nicolaou, G. Skokotas, P. Maligres, G. Zuccarello, E.J. Schweiger, K. Toshima, S. Wendeborn, *Angew. Chem. Int. Ed. Engl.* 28 (1989) 1272–1275; (b) K.C. Nicolaou, S. Wendeborn, P. Maligres, K. Isshiki, N. Zein, G. Ellestad, *Angew. Chem. Int. Ed. Engl.* 30 (1991) 418–420; (c) B. Breiner, J.C. Schlatterer, S.V. Kovalenko, N.L. Greenbaum, I.V. Alabugin, *Angew. Chem. Int. Ed.* 45 (2006) 3666–3670.
- [17] (a) B. Shan, J.C. Medina, E. Santha, W.P. Frankmoelle, T.-C. Chou, R.M. Learned, M.R. Narbut, D. Stott, P. Wu, J.C. Jaen, T. Rosen, P.B.M.W.M. Timmermans, H. Beckmann, *Proc. Natl. Acad. Sci.* 96 (1999) 5686–5691; (b) P. Frankmoelle, J. C. Medina, B. Shan, M. R. Narbut, H. Beckmann, *Drug Metabolism and Disposition*, 28, (2000), 951– 958; (c) S.M. Rubenstein, V. Baichwal, H. Beckmann, D.L. Clark, W. Frankmoelle, D. Roche, E. Santha, S. Schwender, M. Thoolen, Q. Ye, J.C. Jaen, *J. Med. Chem.* 44 (2001) 3599–3605.
- [18] J.D. Berlin, A. Venook, E. Bergsland, M. Rothenberg, A.C. Lockhart, L. Rosen, *Clin. Colorectal Cancer*. 7 (2008) 44–47.
- [19] (a) S. Di Stefano, M. Mazzonna, E. Bodo, L. Mandolini, O. Lanzaunga, *Org. Lett.* 13, (2011), 142–145; (b) B.W. Vos, W.S. Jenks, *J. Am. Chem. Soc.* 124, (2002), 2544–2547.
- [20] D.J. Mayo, D.P. Turner, B.E. Zucconi, A.H. Predecki, *Bioorg. Med. Chem. Lett.* 17 (2007) 6116–6118.
- [21] For selected examples see: (a) R.L. Funk, E.R.R. Young, R.M. Williams, M.F. Flanagan and T.L. Cecil, *J. Am. Chem. Soc.*, 118, (1996) 3291–3292; (b) A. Evenzahav, N. J. Turro, *J. Am. Chem. Soc.* 120 (1998) 1835–1841; (c) P.J. Benites, R.C. Holmberg, D.S. Rawat, B. J. Kraft, L.J. Klein, D.G. Peters, H. H. Thorp and J. M. Zaleski, *J. Am. Chem. Soc.*, 125 (2003) 6434; (d) M. Schmitt, G. Viola, F. Dall’Acqua, G. Morbach, *Chem. Commun.* (2003) 646–647; (e) S.V. Kovalenko, I.V. Alabugin, *Chem. Commun.* (2005) 1444–1446.
- [22] For a review see: B. Breiner, K. Kaya, S. Roy, W.-Y. Yang, I.V. Alabugin, *Org. Biomol. Chem.*, 10 (2012) 3974–3987.
- [23] (a) W.-Y. Yang, B. Breiner, S.V. Kovalenko, C. Ben, M. Singh, S. N. LeGrand, Q.-X.A. Sang, G.F. Strouse, J.A. Copland, I.V. Alabugin, *J. Am. Chem. Soc.*, 131 (2009) 11458–11470; (b) Breiner, B.; Schlatterer, J. C.; Kovalenko, S. V.; Greenbaum, N. L.; Alabugin, I. V. *Proc. Natl. Acad. Sci. U.S.A.* 104 (2007) 13016; (c) W.-Y. Yang, S. Roy, B. Phrathep, Z. Rengert, R. Kenworthy, D.A.R. Zorio, I.V. Alabugin, *J. Med. Chem.* 54 (2011) 8501–8516; (d) K. Kaya, S. Roy, J.C. Nogue, J.C. Rojas, Z. Sokolij, D.A.R. Zorio, I.V. Alabugin, *J. Med. Chem.* 59 (2016) 8634–8647.

Highlights

- Novel Enediynes as a potential antiproliferative drugs.
- Dual Targeting of Microtubules and DNA.
- IC₅₀ ranging from 0.6 to 3.4 μ M against a broad panel of human cancer cells.
- Enhanced activity upon photoactivation.
- Compound **4i** showed double-stranded DNA cleavage.